国务院研究优化集采：第11批药品集采将至，报价机制调整在即

Core Viewpoint - The Chinese government is optimizing the centralized procurement policy for drugs and medical supplies to ensure quality and affordability for the public, indicating potential issues with the quality of some procured drugs and the need for further exploration of the policy [1][2][3]. Group 1: Policy Optimization - The State Council is focusing on enhancing the evaluation of drug procurement policies and ensuring the quality of drugs and medical supplies [1][2]. - The 11th batch of drug procurement is expected to take place in 2025, with a target of 700 varieties to be procured [1]. - The introduction of a new pricing mechanism aims to prevent extreme low pricing that could harm consumer confidence and the survival of companies [3][4]. Group 2: Pricing Mechanism Adjustments - The new draft policy suggests a price difference limit of 1.8 times the lowest bid for the same drug, with a focus on avoiding abnormal low pricing [4]. - The extreme low prices observed in recent procurements have raised concerns about their sustainability and potential negative impacts on the pharmaceutical industry [3][7]. - The rapid increase in B-license companies, which do not produce drugs themselves, has led to concerns about quality and market stability [7][8]. Group 3: Quality Assurance - Discussions around the relationship between low prices and drug quality have intensified, especially following the disqualification of a company for failing to meet quality standards [6][7]. - The government emphasizes the need for a transparent regulatory mechanism to ensure drug quality while maintaining competitive pricing [5][6]. - The focus on quality is crucial as low prices could lead to reduced profit margins for manufacturers, potentially impacting their ability to maintain quality and innovate [7][8]. Group 4: Future Directions - The upcoming 11th batch of procurement is seen as a significant reform, reflecting lessons learned from previous rounds and aiming for a more balanced approach to pricing and quality [10][11]. - There is a call for a unified and transparent procurement platform to ensure fair pricing and quality assurance in drug procurement [10][11]. - The need to balance innovation and quality in drug procurement is highlighted, with suggestions to incorporate clinical benefits into the procurement evaluation criteria [11].